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Resistance to
Dihydroartemisinin 
To the Editor: The emergence of
widespread resistance to chloroquine
and sulfadoxine-pyrimethamine in
Africa has caused a sharp rise in
deaths from malaria. The World
Health Organization therefore urgent-
ly recommends replacement of these
drugs, particularly with combinations
that include an artemisinin compound
(AC) (1). In 2006, although >40 coun-
tries have adopted artemisinin-based
combination therapies as their first-
line treatment for malaria, only a few
of these countries actually use these
combination therapies because of lim-
iting factors such as high cost (2).
When used as monotherapy, ACs are
associated with high rates of recrude-
scence, possibly because of their short
elimination half-lives (3). Most
artemisinin-based combination thera-
pies contain, in addition to ACs, a
partner drug against which resistance
has already developed (e.g., meflo-
quine, amodiaquine, lumefantrine);
reports of relatively low efficacy of
the combination artesunate-amodi-
aquine have been recently published
(4). In 2005, Jambou et al. claimed to
have found the first cases of in vitro
Plasmodium falciparum resistance to
ACs (5). 
We assessed the in vitro suscepti-
bility to dihydroartemisinin (dhART),
the biologically active metabolite of
artemisinin derivatives, of P. falci-
parum isolates from travelers return-
ing to France from various African
countries during 2004–2006. In addi-
tion, we searched for polymorphism
in the P. falciparum adenosine
triphosphatase-6 (PfATPase6) gene,
which was reported to be associated
with in vitro artemether resistance (5).
We also studied polymorphism (a 3-
bp indel) in the gene of the ABC
transporter G7, which was reported in
2005 to be associated with in vitro
response to artesunate (6).
Determination of in vitro dhART
susceptibility by using the isotopic
semimicrotest method (7) was suc-
cessful for 397 isolates. The most rep-
resented countries were Cameroon
(17%), Côte d’Ivoire (14.5%), Mali
(12%), Comoros Islands (8.5%), and
Senegal (6.5%). Patients were <75
years of age (mean 31, SD 17 years),
and the male:female ratio was 1.5:1.
The 50% inhibitory concentration
(IC50) values ranged from 0.02 to 31.8
nmol/L, with a geometric mean of
1.31 nmol/L and a median of 0.68
nmol/L. IC50 values were <1 nmol/L
for 264 isolates, 1–10 nmol/L for 127,
and >10 nmol/Lfor 6. Thus, some iso-
lates showed a diminished suscepti-
bility to dhART, but only 1 isolate had
an IC50 >30 nmol/L (31.8 nmol/L).
DNA sequencing of 900-bp and
240-bp PCR products, including the
769 and the 243/263 PfATPase6
codons, respectively, was performed
in a subsample of 154 isolates. All
isolates had the S769 wild codon
except 1 susceptible isolate (IC50 =
0.83 nmol/L), which had a S769N
mutant type codon (Table). We found
no polymorphism in codon 263. This
position may be scrutinized to moni-
tor anticipated artemisinin resistance,
according to a recently published
structure-function study (8). Con-
versely, we found 2 isolates that
had IC50 values of 4.2 nmol/L andLETTERS
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6.4 nmol/Land that showed an H243Y
mutant type codon. The role of such a
polymorphism appears unclear. We
found no association between the 3-bp
indel in G7 and in vitro dhART sus-
ceptibility because mutants were regu-
larly distributed in highly susceptible
isolates and in isolates having a dimin-
ished susceptibility.
For our samples obtained during
2004–2006, the geometric mean IC50
value for dhART was very close to
values found in Cameroon during
1997–1998 (mean dhART IC50 = 1.11
nmol/L) (9), in Senegal in 2001 (mean
artemether IC50 = 1.3 nmol/L) (5), and
in Republic of Congo during
2005–2006 (mean dhART IC50 = 1.02
nmol/L) (10). Ringwald et al.
observed a narrower range of IC50s,
but their series included only 65 sam-
ples (9). Previous comparisons
between ACs suggested that dhART is
1.7 times more potent than artemether
against  P. falciparum (9). Thus, the
highest IC50 value for artemether
observed by Jambou et al. in Senegal
(44.7 nmol/L) (5) is comparable to the
highest IC50 value for dhART in our
series (31.8 nmol/L). The resistance
levels of ACs are still undefined. For
artemether, Jambou et al. used a
threshold of 30 nmol/L to evaluate the
association between the S769N muta-
tion and in vitro susceptibility. The
presence of ATPase6 S769N was not
associated with diminished in vitro
susceptibility in our series.
Conversely, the only S769N mutant
that we observed was found in a fully
susceptible isolate. Thus, we con-
firmed that polymorphism exists in
this gene in positions 769 and 243, but
we did not prove an association
between these point mutations and
resistance to ACs. Similarly, our
results did not support the hypothesis
of an association between the 3-bp
indel in G7 and resistance to ACs.
ACs, considered the most impor-
tant class of antimalarial drugs, merit
close surveillance for susceptibility.
Continued monitoring of the efficacy
of their associated partner drugs also
appears to be essential.
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Real-time PCR for
Francisella 
tularensis
Types A and B 
To the Editor: Francisella
tularensis, the etiologic agent of
tularemia, is highly infectious and
considered a potential bioweapon
(1–3). Although 4 subspecies of F.
tularensis are recognized, most cases
of tularemia are due to infection by
subsp. tularensis (type A) or holarcti-
ca (type B). North America is the
only region where both type A and
type B cause human disease.
Subspecies novicida is also found in
North America, but it is of reduced
virulence. Disease incidence attribut-
able to either type A or type B is